Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer:final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
作者机构：Guangdong Provincial People’s HospitalGuangdong Academy of Medical Sciences510080 GuangzhouChina Peking University Cancer Hospital and Institute100142 BeijingChina Fujian Medical University Union Hospital350001 FuzhouChina First Affiliated Hospital of Dalian Medical University116011 DalianChina Peking University People’s Hospital100044 BeijingChina Zhejiang Cancer Hospital310022 HangzhouChina Zhongshan Hospital200032 ShanghaiChina Guangzhou Liuhuaqiao Hospital510000 GuangzhouChina Jilin Provincial Tumor Hospital130012 ChangchunChina Jiangsu Cancer Institute and Hospital210009 NanjingChina Tianjin Medical University Cancer Institute and Hospital300060 TianjinChina First Affiliated Hospital of Xi’an Jiaotong University710061 Xi’anChina
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2023年第8卷第3期
页 面：1310-1317页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：The authors thank all patients and their families.The authors would like to acknowledge the editorial support provided by Keyra Martinez Dunn MD of Edanz(www.edanz.com) which was funded by Shanghai Roche Pharmaceutical Ltd.This study was funded by the Chinese Thoracic Oncology Group(CTONG) Shanghai Roche Pharmaceutical Ltd
主 题：neoadjuvant cisplatin chemotherapy
摘 要：EMERGING-CTONG 1103 showed improved progression-free survival(PFS)with neoadjuvant erlotinib *** for patients harbouring EGFR sensibility mutations and R0 resected stage IIIA-N2 non-small cell lung cancer(NSCLC)(NCT01407822).Herein,we report the final *** patients were randomly allocated 1:1 to the erlotinib group(150 mg/day orally;neoadjuvant phase for 42 days and adjuvant phase to 12 months)or to the GC group(gemcitabine 1250 mg/m2 plus cisplatin 75 mg/m2 intravenously;2 cycles in neoadjuvant phase and 2 cycles in adjuvant phase).Objective response rate(ORR),complete pathologic response(pCR),PFS,and overall survival(OS)were assessed along with *** hoc analysis was performed for subsequent treatments after disease *** investigated 72 patients(erlotinib,n=37;GC,n=35),the median follow-up was 62.5 *** median OS was 42.2 months(erlotinib)and 36.9 months(GC)(hazard ratio[HR],0.83;95%confidence interval[CI],0.47-1.47;p=0.513).The 3-and_(5-y)ear OS rates were 58.6%and 40.8%with erlotinib and 55.9%and 27.6%with GC(p_(3-y)=0.819,p_(5-y)=0.252).Subsequent treatment was administered in 71.9%and 81.8%of patients receiving erlotinib and GC,respectively;targeted therapy contributed mostly to OS(HR,0.35;95%CI,0.18-0.70).After disease progression,the ORR was 53.3%,and the median PFS was 10.9 months during the EGFR-TKI *** postoperative therapy,grade 3 or 4 adverse events(AEs)were 13.5%in the erlotinib group and 29.4%in the GC *** serious adverse events were *** exhibited clinical feasibility for resectable IIIA-N2 NSCLC over chemotherapy in the neoadjuvant setting.
维普期刊数据库